Search results

Wilkinson Group: Blood Stem Cell Fitness Mechanisms

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine

Haematopoietic stem cells (HSCs) support blood system homeostasis and are also used clinically in cell and gene therapies. We are studying the biology of this important stem cell population with the aim of developing new HSC-based therapies.

Chakraverty Group: Haematopoietic Transplantation and Immunotherapy

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.

Psaila Group: Normal and Malignant Megakaryocyte and Platelet Biology

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

We apply state-of-the-art approaches to study normal and malignant megakaryocyte biology and bone marrow fibrosis, to identify new targets for therapy for patients with myeloproliferative neoplasms. We are also interested in the role of platelets as biomarkers for early cancer detection.

Davies Group: Genomics and Clinical Genome Editing

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

We are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies

Patel Group: Two tier protection and metabolic genotoxicity during blood production

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine

We study endogenous DNA damage caused by metabolites and their impact on the function of vertebrate stem cells and the ageing process

Chapman Group: Recombination mechanisms in immunity and cancer

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine

de Bruijn Group: Developmental Haematopoiesis

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.

Higgs Group: Laboratory of Gene Regulation

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

We use state-of-the-art laboratory and computational approaches to understand how mammalian genes are switched on and off during development and differentiation and how this goes awry in human genetic diseases.

Mead Group: Haematopoietic Stem Cell Biology

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

The Haematopoietic Stem Cell Biology (HSCB) Laboratory is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.

Vyas Group: Biology and Treatment of Human Myeloid Cancers

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

We aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.

Hughes Group: Genome Biology

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

Using genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.

Milne Group: Epigenetic Control of Gene Expression in Leukaemia and Haematopoiesis

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

Aberrant epigenetic changes are a driving force in many human cancers. The focus of our lab is centred on understanding how epigenetics impacts gene regulation so that this information can potentially be used to develop new therapeutic strategies.

Gibbons Group: ATRX Group

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

We are interested in the function of the chromatin remodelling factor ATRX and how mutations in this factor lead to human disease.

Nerlov Group: Hematopoietic Stem Cell Genetics

MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences

Hematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.